Twist Bioscience Corporation (NASDAQ:TWST) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC lifted its stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 6,499.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,366 shares of the company's stock after acquiring an additional 28,921 shares during the period. GAMMA Investing LLC's holdings in Twist Bioscience were worth $1,153,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in TWST. Vanguard Group Inc. lifted its position in shares of Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after buying an additional 189,791 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Twist Bioscience by 34.5% in the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock worth $1,761,000 after buying an additional 9,722 shares during the last quarter. Teacher Retirement System of Texas raised its stake in shares of Twist Bioscience by 18.9% during the 4th quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company's stock worth $807,000 after acquiring an additional 2,755 shares in the last quarter. Stifel Financial Corp raised its stake in shares of Twist Bioscience by 19.6% during the 4th quarter. Stifel Financial Corp now owns 8,331 shares of the company's stock worth $387,000 after acquiring an additional 1,364 shares in the last quarter. Finally, US Bancorp DE lifted its position in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after acquiring an additional 601 shares during the last quarter.

Insider Activity

In related news, CEO Emily M. Leproust sold 5,042 shares of the business's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $189,831.30. Following the completion of the transaction, the chief executive officer now directly owns 655,432 shares in the company, valued at $24,677,014.80. The trade was a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Patrick John Finn sold 2,058 shares of the stock in a transaction dated Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total value of $82,299.42. Following the sale, the chief operating officer now directly owns 265,460 shares in the company, valued at $10,615,745.40. This represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,673 shares of company stock valued at $720,412 in the last ninety days. Insiders own 3.01% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on TWST. The Goldman Sachs Group cut their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Guggenheim restated a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. Barclays decreased their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Finally, Robert W. Baird lowered their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Stock Performance

TWST traded up $1.97 on Thursday, reaching $35.89. 1,072,492 shares of the stock were exchanged, compared to its average volume of 974,847. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.51 and a quick ratio of 4.24. The company's 50-day moving average price is $33.83 and its 200 day moving average price is $41.33. The firm has a market capitalization of $2.15 billion, a PE ratio of -11.04 and a beta of 2.38. Twist Bioscience Corporation has a fifty-two week low of $27.12 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.